Phase 1 Study of Oral LY4584180 Alone or with Rituximab in Adults with Previously Treated Blood Cancers

What this Trial Is About

Researchers are studying LY4584180 to evaluate its safety, how well it works, and how the body processes this drug in adults who have blood cancers that have been treated before. This study focuses on participants with specific types of lymphoma and other related blood cancers who have already tried at least two previous treatments or are not eligible for other available therapies. The study is a Phase 1a1b clinical trial aimed at understanding the drugs effects and tolerability. Participants will receive LY4584180 either alone by mouth or combined with rituximab given through an IV infusion. Different study groups will receive varying doses or combinations of these treatments, with some groups focusing on dose escalation, optimization, or expansion. The treatment is administered orally for LY4584180 and intravenously for rituximab, depending on the group assignment. Throughout the study, participants will be monitored for side effects such as dose-limiting toxicities and serious adverse events related to the drug. Researchers will also measure the drug levels in the bloodstream and observe tumor responses over a period that can last up to three years. The total duration for each participant, including screening, is about nine months or longer, with ongoing safety and effectiveness assessments conducted regularly during this time.

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers